Storia in 4 fonti

Upfront Ivonescimab Plus Chemo Bests PD-1 Inhibitor Combo in Advanced NSCLC

HARMONi-6 showed 34% drop in death risk, but trial had an all-Asian population, expert warned

Raccontata damedpagetoday.combiopharmadive.comstatnews.commorningstar.com

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo1 g fa

Upfront Ivonescimab Plus Chemo Bests PD-1 Inhibitor Combo in Advanced NSCLC

HARMONi-6 showed 34% drop in death risk, but trial had an all-Asian population, expert warned

originale

morningstar.com1 g fa

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior…

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

Leggi questa versione → originale

biopharmadive.com2 g fa

Akeso, Summit drug extends survival in closely watched lung cancer trial

Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies known as "PD-1/VEGF inhibitors."

Leggi questa versione → originale

statnews.com1 g fa

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

Akeso and Summit Therapeutics' ivonescimab reduced the risk of death by 34% in squamous non-small cell lung cancer patients versus standard treatment, in a Phase III trial published in The Lancet. For biotech and pharma-adjacent tech buyers, the result validates dual-mechanism oncology biologics and strengthens Summit's pipeline valuation ahead of potential ex-China regulatory filings.

Leggi questa versione → originale

Timeline cronologica

1. sabato 30 maggio 2026·medpagetoday.com
   

   Drug Combo for Lung Cancer Beats Pembrolizumab in First-Line Trial

   Antibody-drug conjugate plus pembrolizumab superior to pembrolizumab alone in PD-L1 expressors

2. domenica 31 maggio 2026·biopharmadive.com
   

   Akeso, Summit drug extends survival in closely watched lung cancer trial

   Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies…

3. domenica 31 maggio 2026·statnews.com
   

   Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

   A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.

4. domenica 31 maggio 2026·morningstar.com
   

   HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in…

   HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to…

5. domenica 31 maggio 2026·morningstar.com
   

   Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy…

   Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with…

6. domenica 31 maggio 2026·medpagetoday.com
   

   Upfront Ivonescimab Plus Chemo Bests PD-1 Inhibitor Combo in Advanced NSCLC

   HARMONi-6 showed 34% drop in death risk, but trial had an all-Asian population, expert warned